EyePoint, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EYPT Nasdaq 2830 eyepoint.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for EyePoint, Inc.

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - May 26th, 2026 10:04 am
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - May 20th, 2026 11:13 pm
EyePoint Announces Participation at Upcoming Investor Conferences - May 19th, 2026 5:00 am
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 18th, 2026 5:00 am
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - May 17th, 2026 12:18 pm
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - May 17th, 2026 7:14 am
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - May 14th, 2026 5:00 am
EyePoint (EYPT) Q1 2026 Earnings Transcript - May 7th, 2026 9:51 am
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 7th, 2026 6:30 am
Eyepoint Pharmaceuticals Q1 Earnings Call Highlights - May 6th, 2026 9:54 am
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates - May 6th, 2026 6:25 am
Is It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price Surge - May 6th, 2026 6:15 am
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments - May 6th, 2026 5:00 am
How The EyePoint (EYPT) Story Is Shifting With DURAVYU And Phase 3 DME Trials - May 5th, 2026 4:09 am
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - Apr 29th, 2026 5:00 am
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last? - Apr 2nd, 2026 12:55 am
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Mar 25th, 2026 8:18 am
How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Mar 20th, 2026 8:05 pm
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - Mar 16th, 2026 5:56 pm